From Jyothi Challa, MD, OHC Medical Oncologist and Hematologist

July 11, 2019

The cancer experts at OHC are bringing new hope to people living with liver cancer with the use of newer treatments that are showing promising results.

Liver cancer is the only cancer in the United States with incidence rates that continue to rise every year. Plus, standard chemotherapy hasn’t been very effective over the years in treating liver cancer. OHC has been using new targeted drugs and immunotherapy drugs that work differently from standard chemotherapy drugs and are showing positive results.

Targeted Medicines
The most common targeted drug for liver cancer is sorafenib, considered to be the standard-of-care treatment. Several other drugs have been approved for use when sorafenib is no longer helpful, including ramucirumab, which was approved by the Food and Drug Administration earlier this year. In clinical trials, ramucirumab showed a significant survival benefit in patients with extremely high AFP levels (indicators of liver cancer).

OHC also uses two immunotherapy drugs – pembrolizumab and nivolumab – that have been approved as a second line of treatment for liver cancer. Immunotherapy drugs boost the immune response against cancer cells, which can shrink some tumors or slow their growth. They provide patients with another option when their liver cancer hasn’t responded to sorafenib.

The past couple of years have been notable in terms of treatments for liver cancer. For years, there were no real improvements, but that’s changing. We’re seeing promising results with the targeted and immunotherapy drugs, and giving patients a new sense of hope. OHC is proud to always be at the forefront of new approaches to beat cancer.

At OHC, our renown clinical research experts are bringing the latest treatments to our community to help patients win their battle with cancer. If you or someone you know has been diagnosed with cancer, contact OHC to learn more about treatment options or for a second opinion at or call 1-800-710-4674.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *